OncoMatch

OncoMatch/Clinical Trials/NCT05952453

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

Is NCT05952453 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Carboplatin and olaparibp, embro for ovarian cancer.

Phase 2RecruitingUniversity of Alabama at BirminghamNCT05952453Data as of May 2026

Treatment: Carboplatin · olaparibp, embrothis is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or Stage IV prior to surgery to remove the tumor. After surgery there will be additional chemotherapy given.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Disease stage

Required: Stage III, IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: systemic anti-cancer therapy

Participant has received prior treatment for advanced or metastatic OC, including radiation or systemic anti-cancer therapy (e.g., chemotherapy, hormonal therapy, immunotherapy, investigational therapy).

Cannot have received: PARP inhibitor (olaparib)

Participant has received prior therapy with olaparib or with any other PARP inhibitor.

Lab requirements

Blood counts

Absolute neutrophil count (ANC) ≥1500/μL; Platelets ≥100,000/μL; Hemoglobin ≥8.0 g/dL or ≥5.6 mmol/L

Kidney function

Creatinine OR measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 × ULN OR ≥51 mL/min for participant with creatinine levels >1.5 × institutional ULN

Liver function

Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN; AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver metastases)

Participant has adequate organ function as follows; ... see full criteria

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • O'Neal Comprehensive Cancer Center at UAB · Birmingham, Alabama

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify